Trading Volume Is Exploding in Sigyn Therapeutics (SIGY) — Is a Strategic Merger on the Horizon?

In the micro-cap market, some of the largest percentage stock gains in history have occurred when a small, little-known company suddenly becomes the vehicle for a strategic merger or reverse-merger transaction.

​

Those events often happen quietly at first — with subtle corporate signals, shareholder communications hinting at strategic alternatives, and a sudden surge in trading volume as investors begin positioning early.

​

Right now, Sigyn Therapeutics (OTCQB: SIGY) may be entering exactly that kind of moment.

​

This last Friday, Sigyn Therapeutics announced a possible merger in their press release.

 

And the market appears to be noticing.

 

In recent sessions, trading volume in SIGY has increased sharply, a development that frequently precedes heightened investor awareness and speculative positioning in micro-cap companies exploring transformational corporate transactions.

With a tiny share structure, breakthrough medical technologies, and newly disclosed merger discussions, Sigyn may now be positioning itself for what could become a major strategic event.

 

A Company Now Actively Discussing Merger Opportunities

Sigyn recently released a shareholder update that contained a highly notable disclosure:

The company has initiated discussions with a Nasdaq-listed company that may need a merger partner.

That statement alone immediately captured the attention of micro-cap investors.

 

Volume Surging as Investors Begin to Pay Attention

One of the most intriguing developments surrounding SIGY right now is the rapid acceleration in trading activity.

Micro-cap investors often watch volume closely because volume spikes frequently precede major corporate announcements.

When trading activity suddenly expands in a company with:

• a very small share structure
• potential merger discussions
• valuable intellectual property

…it can signal that investor awareness is spreading quickly.

​

CardioDialysis: A Potential Billion-Dollar Medical Opportunity

At the center of Sigyn’s technology platform is CardioDialysis™, a dialysis-based therapy designed to reduce cardiovascular risk.

Cardiovascular disease remains the leading cause of death globally, creating one of the largest medical markets in the world.

Sigyn’s approach focuses on removing harmful inflammatory molecules and cholesterol-transporting lipoproteins from the bloodstream during dialysis treatments.

​

This concept builds upon lipoprotein apheresis, a therapy that research suggests can significantly reduce cardiovascular events.

 

The potential economics are striking.   A primary objective of cardiovascular disease therapies is to reduce the incidence of heart attacks, strokes, and other Major Adverse Cardiovascular Events (MACE). LDL-C reducing statins (Lipitor, Crestor, and Zocor), the leading class of drugs to treat cardiovascular disease are associated with 25% reductions in MACE.

Source Publication Link:

https://pmc.ncbi.nlm.nih.gov/articles/PMC12359277/

Whereas the American Heart Association (AHA) recently reported the use of blood purification to reduce LDL-C and Lipoprotein(a) levels (lipoprotein apheresis) is associated with 75% to 95% reductions in MACE.  

As per the AHA report, blood purification to reduce circulating levels of LDL-C and Lipoprotein(a), otherwise known as lipoprotein apheresis, is an FDA-approved precedent proven to reduce MACE in those with cardiovascular disease. However, the broad adoption of lipoprotein apheresis is constrained by delivery infrastructure, with treatments being limited to approximately 60 specialized apheresis centers in the United States.

CardioDialysis is not constrained by delivery infrastructure as it is deployed for use on dialysis machines already located at more than 7,500 kidney dialysis clinics in the U.S. alone. Lipoprotein apheresis devices do not operate on dialysis machines. 

 

Sigyn estimates that treating just 1% of the approximately 550,000 end-stage renal disease patients in the United States could generate more than a billion dollars in annual revenue at roughly $2,500 per weekly treatment per patient..

​

Why Dialysis Giants Like Fresenius and DaVita Could Be Highly Motivated to Adopt CardioDialysis

Another powerful element of the Sigyn story is the potential financial impact that CardioDialysis could have for the world’s largest dialysis providers.

​

Two companies dominate the dialysis industry globally: Fresenius Medical Care and DaVita Inc.. Together, these companies treat a substantial percentage of the more than 550,000 end-stage renal disease (ESRD) patients in the United States and operate thousands of dialysis clinics worldwide.

​

For these providers, adding a new reimbursable therapy to existing dialysis treatments could represent an enormous incremental revenue opportunity.

 

CardioDialysis is particularly interesting because it is designed to be integrated directly into dialysis sessions that patients are already receiving multiple times per week. That means the infrastructure — clinics, machines, patient flow, and trained staff — already exists.

If Sigyn’s technology were validated clinically and adopted commercially, dialysis providers would not necessarily need to build entirely new treatment centers. Instead, they could potentially add CardioDialysis as an additional therapy performed during routine dialysis sessions.

​

The economics of that scenario could be substantial.

Sigyn has previously suggested that a weekly treatment could be reimbursed at approximately $2,500 per treatment. Even if only a small percentage of dialysis patients were treated, the revenue impact for dialysis providers could be dramatic.

For example:

• Treating 5,000 patients weekly could represent roughly $650 million in annual treatment revenue.
• Treating 10,000 patients could approach $1.3 billion annually.
• If adoption expanded to tens of thousands of patients globally, the revenue opportunity could scale into multiple billions of dollars per year.

 

For dialysis providers operating in a mature industry with relatively stable growth rates, a new therapy capable of generating billions in incremental revenue would be highly attractive.

​

Even more importantly, CardioDialysis targets cardiovascular risk, which is the leading cause of death among dialysis patients. If the therapy can demonstrate meaningful reductions in cardiovascular events, providers would not only gain a new revenue stream — they could potentially improve patient survival and long-term outcomes.

​

That combination of clinical benefit and major new revenue potential is exactly the type of innovation that large healthcare providers often move quickly to evaluate.

​

In that context, Sigyn’s CardioDialysis technology could eventually become far more than just a single therapeutic product. It could represent an entirely new category of treatment within the global dialysis industry.

​

And for companies like Fresenius and DaVita, the ability to add a high-value cardiovascular therapy to existing dialysis infrastructure could transform the economics of kidney care worldwide.

​

For a company currently trading with a tiny micro-cap valuation, that scale of potential revenue opportunity is enormous.

This type of high-value medical technology could easily become the anchor asset in a strategic merger or acquisition.

 

Multiple Technologies Increase Strategic Value

Beyond CardioDialysis, Sigyn has also developed additional technologies that could significantly increase its appeal to strategic partners.

 

These include:

ImmunePrep™ – designed to enhance immunotherapy antibodies
ChemoPrep™ – designed to improve chemotherapy delivery
ChemoPure™ – designed to reduce chemotherapy toxicity

 

These programs focus on improving the performance and safety of existing cancer treatments — an approach that pharmaceutical companies often find highly attractive because it can expand the commercial value of already-approved drugs.

 

Additionally, Sigyn’s blood-purification platform may have potential applications in:

• sepsis
• infectious diseases
• traumatic brain injury
• systemic inflammation

Platform technologies that can address multiple disease areas often carry significant strategic value in the biotechnology sector.

 

Leadership That Has Built Value Before

Another reason investors are paying attention to Sigyn is the leadership behind the company.

 

CEO Jim Joyce previously founded Aethlon Medical, where he helped develop the Hemopurifier device — a technology that received multiple FDA Breakthrough Device designations.

During his tenure, Aethlon eventually achieved a market valuation approaching $200 million, demonstrating his ability to build value around innovative blood-purification technologies.

​

That experience could prove critical as Sigyn navigates potential partnerships, licensing agreements, or merger transactions.

 

A Tiny Share Structure With Enormous Leverage

Perhaps the most explosive factor in the SIGY story is the company’s extremely small share structure.

According to the company’s most recent shareholder update, only 2,330,042 shares were outstanding as of March 11, 2026.

In micro-cap markets, companies with such limited share supply can experience extreme price movements when demand increases.

If a major strategic development were announced — such as a merger, licensing deal, or strategic investment — the limited float could create powerful supply-and-demand dynamics in the stock.

 

The recent spike in trading volume suggests that investors may already be beginning to recognize this leverage.

​

Volume Surging as Investors Begin to Pay Attention

One of the most intriguing developments surrounding SIGY right now is the rapid acceleration in trading activity.

Micro-cap investors often watch volume closely because volume spikes frequently precede major corporate announcements.

When trading activity suddenly expands in a company with:

• a very small share structure
• potential merger discussions
• valuable intellectual property

…it can signal that investor awareness is spreading quickly.

 

The recent increase in SIGY’s trading volume suggests that market participants may already be starting to position ahead of potential strategic developments.

​

In micro-cap markets, once momentum begins building, it can spread rapidly through investor networks, social media communities, and trading platforms.

 

The Setup Investors Are Watching

 

While early-stage biotech investments always carry significant risk, the setup now forming around Sigyn includes several elements that historically attract intense investor interest:

​

• discussions involving a potential Nasdaq merger partner
• exploration of asset sales and strategic transactions
• breakthrough cardiovascular and oncology technologies
• leadership with a proven track record
• an extremely tight share structure
• and rapidly increasing trading volume

 

In the micro-cap world, when corporate catalysts collide with limited share supply, the resulting price moves can be dramatic.

With merger discussions underway and trading activity accelerating, Sigyn Therapeutics may now be entering a period where the market begins to reassess the company’s potential.

 

For investors who specialize in identifying early-stage transformation stories, SIGY may be one of the most intriguing micro-cap situations developing right now.

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.